Mitralign is a technology company.
Mitralign has raised $58.0M across 2 funding rounds.
Mitralign has raised $58.0M in total across 2 funding rounds.
Mitralign has raised $58.0M in total across 2 funding rounds.
Mitralign's investors include Qiming Venture Partners, 4See Ventures, Forbion.
Mitralign is a medical technology company developing catheter-based systems for percutaneous treatment of functional mitral regurgitation (FMR) and tricuspid regurgitation, emulating surgical annuloplasty by plicating the dilated valve annulus.[1][2][3] Its flagship Mitralign Percutaneous Annuloplasty System (MPAS) and Trialign System target patients with severe symptomatic valve issues (MR ≥ 3+), serving interventional cardiologists and patients ineligible for open surgery, addressing a life-threatening condition affecting millions in the U.S. alone.[2][6] Founded in 2004 and based in Tewksbury, Massachusetts, the venture-backed firm (Series F, $153.68M raised) remains operational but shows limited recent funding activity, with its last raise of $9.77M occurring seven years ago; it has pursued early feasibility studies like SCOUT I/II and received CE Mark for MPAS in 2016.[1][6]
Mitralign was founded in 2004 in Tewksbury, Massachusetts, as a medical device innovator focused on less-invasive heart valve repair.[1][2] Specific founders are not detailed in available records, but the company emerged amid growing demand for transcatheter alternatives to surgical interventions for functional mitral regurgitation, a condition linked to heart failure.[3][4] Early development centered on the MPAS, mimicking surgical suture annuloplasty via catheter-delivered implants.[1][3] Pivotal moments include CE Mark approval for MPAS in 2016, U.S. enrollment in the SCOUT Study that year, completion of SCOUT I enrollment in 2017, and a $39.8M Series E round; Edwards Lifesciences later acquired certain assets, signaling validation in structural heart tech.[1][6]
Mitralign rides the structural heart disease wave, particularly transcatheter valve repair, where markets like TAVR exceed $1B and mitral/tricuspid tools address unmet needs beyond MitraClip (50,000+ patients, $250M+ sales).[6][7] Timing aligns with aging populations driving FMR prevalence (4M U.S. cases) and shifts to minimally invasive "toolbox" approaches combining annuloplasty with clips or bands.[2][7] Favorable forces include regulatory nods like CE Mark and investor interest (e.g., Series E), plus Edwards' asset acquisition, amplifying ecosystem influence amid competitors like Cardioband and Carillon.[1][6][7] It contributes to diversified mitral repair options, enabling combo therapies in Europe and pushing U.S. feasibility trials.
Mitralign's investigational systems position it for growth in transcatheter tricuspid/mitral repair, potentially via partnerships or full acquisition post-Edwards deal, as structural heart tech expands.[1][5][6] Trends like ventricle remodeling tools and multi-device strategies will shape progress, with SCOUT data and CE Mark paving FDA paths.[6][7] Its influence may evolve through integration into larger portfolios, offering lifeline therapies for millions, building on its direct annuloplasty innovation to redefine valve repair accessibility.[2][3]
Mitralign has raised $58.0M across 2 funding rounds. Most recently, it raised $23.0M Series E in December 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2014 | $23.0M Series E | Qiming Venture Partners | |
| May 1, 2012 | $35.0M Series D | 4See Ventures, Forbion |